Rejoyn: FDA Cleared First Prescription Digital Therapeutic for MDD

On April 01, 2024: Otsuka and Click Therapeutics announced the FDA Clearance of Rejoyn™: the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms.
Watch this UA-cam video, where Dr. Harvinder Singh has summarized Rejoyn in the following sections:
1. Indication
2. Product Description
3. Recommended Treatment Schedule
4. Alternate Treatment Schedule
5. Mechanism of Action
6. Clinical Trial Data: Mirai Trial
7. Adverse Events: Suicidality
8. How to Use/Prescribe?
Read our blog post here: psychiatryeducationforum.com/...